Is Oscar Health (OSCR) One of the Under-the-Radar AI Stocks to Buy?

Oscar Health Inc. (NYSE:OSCR) is one of theunder-the-radar AI stocks to buy. On January 9, UBS upgraded Oscar Health to Neutral from Sell and raised the price target to $17 from $12. The firm believes that Oscar’s exchange enrollment is holding up better than feared despite the expiration of enhanced subsidies. UBS suggests the shares are fairly priced at this level.

On January 5, Barclays analyst Andrew Mok also upgraded Oscar Health to Equal Weight from Underweight and increased the price target to $18 from $13. The firm anticipates that managed care stocks will benefit in 2026 from potential margin expansion and an investor rotation away from artificial intelligence stocks toward de-rated underperformers.

Furthermore, Andrew Mok suggested that Oscar Health Inc. (NYSE:OSCR) is attractively priced because the market is currently over-discounting the negative impacts of expiring subsidies.

Oscar Health Inc. (NYSE:OSCR) is a healthcare technology company in the US that offers health plans to individuals, families, employees, and small group markets.

While we acknowledge the potential of OSCR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.